Leerink keeps Eli Lilly stock outperform

Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $860 billion at one point.
Eli Lilly Faces ‘Death Cross’ Selloff: This is the Stock's Next Target Price...
Shares of Eli Lilly were already in an intermediate-term decline before the announcement. The stock has dropped 25% from its 2024 highs as investors have been unimpressed with Eli Lilly’s drug pipeline and management.
Leerink keeps Eli Lilly stock outperform on revenue growth
Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently valued at $672.
Has Eli Lilly Stock Peaked?
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Irish Daily Mirror13h
Lily Phillips: Woman who slept with 100 men in 24 hours details 'horrifying' precautions she took
Lily Phillips, who claims to have slept with 100 men in 24 hours, has opened up about the 'horrifying' precautions she took ...
STAT3d
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
FDA approves Eli Lilly's Omvoh for Crohn's disease, showing strong Phase 3 results in clinical remission and intestinal ...
Business Insider4d
Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees Growth In FY25
The Street is looking for revenues of $13.95 billion for the quarter. Lilly now expects approximately $3.5 billion for Mounjaro and $1.9 billion for Zepbound. In total, non-incretin revenue grew ...
E!12d
The Lilly Pulitzer Sunshine Sale Is Here: Snag Rare Deals Up to 70% Off Before They're Gone!
The 2025 Lilly Pulitzer Sunshine Sale has up to 70% off activewear, dresses, sweaters, accessories, home decor, and more. This rare event happens twice a year—shop now before your favorites sell ...
Yahoo Finance9d
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss drugs like Zepbound and Novo Nordisk's Ozempic ...
Ibj.com6d
Lilly shares fall midday on lower fourth quarter revenue guidance
Lilly now expects fourth-quarter revenue to be about $13.5 billion. “While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even ...
As Lilly Stock Tumble on GLP-1 Demand Worries, CEO Says All Is Well
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.